Risultati per: Probiotici: in vivo vs in vitro

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

This randomized trial assesses the effect of remifentanil vs neuromuscular blockers on successful intubation without major complications among patients at risk of aspiration during rapid sequence intubation in the operating room.

In Reply In response to the comments by Dr Koster and colleagues, the OPTIMAL trial enrolled patients aged 18 to 70 years, which is the age range of most patients undergoing adult cardiac bypass surgery in China. We agree that our study results, especially regarding seizures, should be interpreted with caution for patients older than 70 years.

To the Editor A recent study demonstrated a modest but statistically significant reduction in the number of patients needing red blood cell transfusion with use of high-dose vs low-dose tranexamic acid.

This cohort study assesses the associations of time since cancer diagnosis and stage at diagnosis with the risks of pelvic, radial, and vertebral fractures among older cancer survivors vs older adults without a history of cancer.

To the Editor In a recent issue of JAMA Oncology, Shore et al present the results of ENACT, a phase 2 clinical trial randomizing patients with low and favorable intermediate-risk prostate cancer on active surveillance (AS) to receive or not to receive 1 year of antiandrogen treatment with enzalutamide. Findings of this trial suggest a decreased rate of pathologic or therapeutic progression, cancer-positive core rate, and biochemical progression-free survival (bPFS) in the enzalutamide group at 1 year, although no difference in these end points was observed between the groups at 2 years. Based on these results, the authors propose adding enzalutamide to AS for this patient population.

To the Editor We applaud Shore et al for their work with the ENACT randomized clinical trial to improve progression-free survival among men on active surveillance (AS) for prostate cancer (PCa). Their addition of enzalutamide monotherapy to the AS regimen represents the latest pharmacological intervention aimed at delaying PCa progression, mirroring previous attempts including use of dutasteride, bicalutamide, and other drugs that disrupt the androgen axis.

This randomized clinical trial evaluates whether mindfulness-based stress reduction is noninferior to escitalopram in the treatment of anxiety disorders.

To the Editor I read with great interest the ENACT randomized clinical trial by Shore et al. This study has recapitulated the same error as the REDEEM study, which is referenced in the Discussion. REDEEM compared dutasteride, a known prostate cytoreductive drug, with placebo in men on active surveillance. The end point of progression included an increase in the volume of grade group 1 (GG1) cancer. The study showed a 38% reduction in progression, but 100% of this was due to differences in volume progression of GG1 disease. In fact, there was a slightly higher rate of grade progression in the dutasteride arm. Rightly, this progression benefit was not considered meaningful by the prostate cancer community. Guidelines do not recommend 5α-reductase inhibitors for men on surveillance to reduce disease progression rates.

This cross-sectional study analyzes patterns in the rates of routine screening and diagnosis for breast, cervical, and colorectal cancer before and after the COVID-19 pandemic.

In Reply Active surveillance (AS) is the preferred management strategy for low-risk prostate cancer. While AS rates are increasing in clinical practice, its adoption remains suboptimal and is highly variable in the US. The potential benefits of treatments that might provide a durable effect on pathology and delay disease progression in the favorable-risk prostate cancer setting have not been fully elucidated.